The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
Irinotecan is one of the drugs that might be effective against platinum- and taxanes-resistant epithelial ovarian cancer. We investigated efficacy and safety of the weekly dosing schedule of irinotecan. From September 2001 to March 2003, 28 eligible patients who have histologically confirmed epithel...
Saved in:
Published in | Gynecologic oncology Vol. 100; no. 2; pp. 412 - 416 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.02.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Irinotecan is one of the drugs that might be effective against platinum- and taxanes-resistant epithelial ovarian cancer. We investigated efficacy and safety of the weekly dosing schedule of irinotecan.
From September 2001 to March 2003, 28 eligible patients who have histologically confirmed epithelial ovarian cancer, which was resistant or refractory to both platinum and taxanes, were consecutively treated at the National Cancer Center Hospital. Irinotecan (100 mg/m
2) was administered intravenously over 90 min on days 1, 8, and 15. The chemotherapy was repeated every 4 weeks, up to 6 cycles.
A total of 107 treatment cycles of irinotecan were administered to 28 patients. The median number of prior chemotherapy regimen was 3. Among 28 patients, 8 (29%) responded to irinotecan (2 complete responses and 6 partial responses). The median time to progression was 17 weeks. Three patients experienced hematological toxicities of Grade 4. Five patients experienced non-hematological toxicities Grade 3 or 4. No treatment-related death occurred.
The weekly dosing schedule of irinotecan seems to be effective and safe salvage chemotherapy regimen for platinum- and taxanes-resistant or refractory epithelial ovarian cancer. Gastrointestinal toxicities, especially diarrhea, were moderate and manageable in an outpatient setting. |
---|---|
AbstractList | Irinotecan is one of the drugs that might be effective against platinum- and taxanes-resistant epithelial ovarian cancer. We investigated efficacy and safety of the weekly dosing schedule of irinotecan.
From September 2001 to March 2003, 28 eligible patients who have histologically confirmed epithelial ovarian cancer, which was resistant or refractory to both platinum and taxanes, were consecutively treated at the National Cancer Center Hospital. Irinotecan (100 mg/m(2)) was administered intravenously over 90 min on days 1, 8, and 15. The chemotherapy was repeated every 4 weeks, up to 6 cycles.
A total of 107 treatment cycles of irinotecan were administered to 28 patients. The median number of prior chemotherapy regimen was 3. Among 28 patients, 8 (29%) responded to irinotecan (2 complete responses and 6 partial responses). The median time to progression was 17 weeks. Three patients experienced hematological toxicities of Grade 4. Five patients experienced non-hematological toxicities Grade 3 or 4. No treatment-related death occurred.
The weekly dosing schedule of irinotecan seems to be effective and safe salvage chemotherapy regimen for platinum- and taxanes-resistant or refractory epithelial ovarian cancer. Gastrointestinal toxicities, especially diarrhea, were moderate and manageable in an outpatient setting. Irinotecan is one of the drugs that might be effective against platinum- and taxanes-resistant epithelial ovarian cancer. We investigated efficacy and safety of the weekly dosing schedule of irinotecan. From September 2001 to March 2003, 28 eligible patients who have histologically confirmed epithelial ovarian cancer, which was resistant or refractory to both platinum and taxanes, were consecutively treated at the National Cancer Center Hospital. Irinotecan (100 mg/m 2) was administered intravenously over 90 min on days 1, 8, and 15. The chemotherapy was repeated every 4 weeks, up to 6 cycles. A total of 107 treatment cycles of irinotecan were administered to 28 patients. The median number of prior chemotherapy regimen was 3. Among 28 patients, 8 (29%) responded to irinotecan (2 complete responses and 6 partial responses). The median time to progression was 17 weeks. Three patients experienced hematological toxicities of Grade 4. Five patients experienced non-hematological toxicities Grade 3 or 4. No treatment-related death occurred. The weekly dosing schedule of irinotecan seems to be effective and safe salvage chemotherapy regimen for platinum- and taxanes-resistant or refractory epithelial ovarian cancer. Gastrointestinal toxicities, especially diarrhea, were moderate and manageable in an outpatient setting. |
Author | Matsumoto, Koji Yonemori, Kan Shimizu, Chikako Kohno, Tsutomu Andoh, Masashi Fujiwara, Yasuhiro Katsumata, Noriyuki Yamanaka, Yasuhiro |
Author_xml | – sequence: 1 givenname: Koji surname: Matsumoto fullname: Matsumoto, Koji email: kojmatsu@ncc.go.jp – sequence: 2 givenname: Noriyuki surname: Katsumata fullname: Katsumata, Noriyuki – sequence: 3 givenname: Yasuhiro surname: Yamanaka fullname: Yamanaka, Yasuhiro – sequence: 4 givenname: Kan surname: Yonemori fullname: Yonemori, Kan – sequence: 5 givenname: Tsutomu surname: Kohno fullname: Kohno, Tsutomu – sequence: 6 givenname: Chikako surname: Shimizu fullname: Shimizu, Chikako – sequence: 7 givenname: Masashi surname: Andoh fullname: Andoh, Masashi – sequence: 8 givenname: Yasuhiro surname: Fujiwara fullname: Fujiwara, Yasuhiro |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16298422$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kMtu2zAQRYkiQe08vqBAwR-QOyQlRVp0UQTNAzDQTbIWRuQwpSuTBkm70d-XjgNk1xWByznzOBfszAdPjH0RsBIg2m-b1fwy-7CSAE1JViDUJ7YU0DdV2zX9GVsC9FB1sukW7CKlDQAoEPIzW4hW9l0t5ZK9Pv0mntBSnjl6w8lap1HPPFiey9dfoj_TzE1Izr8cQxedD5k0em5D5LsJs_P7bfVGZ3xFT6mKlFzK6DOnnSttJocTDweMrmAF1RSv2LnFKdH1-3vJnu9-Pt0-VOtf94-3P9aVrqXKlbgBO2IHoI0wWJt-VKNtRmiEVFaTbGzfCqxrK-tOqK6m0Vq8gUa1okejRnXJ1KmvjiGlSHbYRbfFOA8ChqPHYTO8eRyOHo9h8Viorydqtx-3ZD6Yd3Gl4PupgMruB0dxSNpROcy4SDoPJrj_DvgHfAOJgg |
CitedBy_id | crossref_primary_10_1111_jog_12631 crossref_primary_10_1007_s00280_014_2418_8 crossref_primary_10_1007_s00520_018_4367_y crossref_primary_10_1111_j_1447_0756_2010_01217_x crossref_primary_10_1111_jog_13203 crossref_primary_10_1097_COC_0b013e3181a650bc crossref_primary_10_1007_s00280_017_3468_5 crossref_primary_10_1586_14737140_8_5_819 crossref_primary_10_3802_jgo_2021_32_e8 crossref_primary_10_1097_IGC_0b013e3181ffbe9f crossref_primary_10_1016_j_ygyno_2007_03_036 crossref_primary_10_1007_s11101_015_9397_1 crossref_primary_10_1093_jjco_hyr201 crossref_primary_10_1007_s00280_015_2680_4 crossref_primary_10_1007_s12032_023_01975_1 crossref_primary_10_2147_OTT_S281302 crossref_primary_10_1016_j_jconrel_2019_09_006 crossref_primary_10_1016_j_ygyno_2018_07_014 crossref_primary_10_1517_13543784_2010_515585 crossref_primary_10_1111_jog_14558 crossref_primary_10_5649_jjphcs_40_454 crossref_primary_10_1517_14656566_8_14_2293 crossref_primary_10_18632_oncoscience_150 crossref_primary_10_1111_jog_13496 crossref_primary_10_1155_2020_1701326 crossref_primary_10_1016_j_ygyno_2014_10_026 crossref_primary_10_1007_s00404_014_3268_7 crossref_primary_10_1007_s10147_008_0765_3 crossref_primary_10_1007_s10147_021_01973_1 crossref_primary_10_1007_s00280_008_0769_8 crossref_primary_10_1002_pds_1180 crossref_primary_10_3892_mco_2017_1258 crossref_primary_10_1021_pr070041v crossref_primary_10_1007_s00280_021_04314_1 crossref_primary_10_3802_jgo_2018_29_e56 crossref_primary_10_1007_s10147_018_1347_7 crossref_primary_10_1007_s00280_017_3363_0 crossref_primary_10_1007_s10147_023_02367_1 crossref_primary_10_1186_1757_2215_6_8 |
Cites_doi | 10.1016/j.ygyno.2003.08.001 10.1006/gyno.2000.6089 10.1200/JCO.1998.16.2.405 10.1200/JCO.2000.18.6.1193 10.1093/jnci/92.9.699 10.1200/JCO.1991.9.3.389 10.1200/JCO.1998.16.10.3345 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 10.1200/JCO.2002.09.130 10.1002/cncr.21287 10.1200/JCO.1996.14.5.1545 10.1200/JCO.1995.13.1.210 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.3.CO;2-X 10.1200/JCO.2003.02.091 10.1200/JCO.1993.11.11.2194 10.1200/JCO.2000.18.17.3093 10.1093/jnci/83.16.1164 10.1016/S0140-6736(03)13718-X 10.1200/JCO.1992.10.2.243 10.1016/S0090-8258(03)00399-8 10.1007/BF00686188 10.1093/jnci/84.12.972 10.1200/JCO.2003.08.058 10.1056/NEJM199601043340101 |
ContentType | Journal Article |
Copyright | 2005 Elsevier Inc. |
Copyright_xml | – notice: 2005 Elsevier Inc. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1016/j.ygyno.2005.10.013 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1095-6859 |
EndPage | 416 |
ExternalDocumentID | 10_1016_j_ygyno_2005_10_013 16298422 S0090825805009017 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAXUO ABBQC ABFNM ABFRF ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LCYCR LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c423t-170fba800cd1da4d9b3bf5b05123fce25f961a44f2481384ebffa7053619ad3b3 |
IEDL.DBID | AIKHN |
ISSN | 0090-8258 |
IngestDate | Thu Sep 26 16:08:46 EDT 2024 Sat Sep 28 07:50:08 EDT 2024 Fri Feb 23 02:31:08 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Irinotecan Second line treatment Taxanes-resistant Ovarian cancer Platinum-resistant Weekly schedule |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c423t-170fba800cd1da4d9b3bf5b05123fce25f961a44f2481384ebffa7053619ad3b3 |
PMID | 16298422 |
PageCount | 5 |
ParticipantIDs | crossref_primary_10_1016_j_ygyno_2005_10_013 pubmed_primary_16298422 elsevier_sciencedirect_doi_10_1016_j_ygyno_2005_10_013 |
PublicationCentury | 2000 |
PublicationDate | 2006-02-01 |
PublicationDateYYYYMMDD | 2006-02-01 |
PublicationDate_xml | – month: 02 year: 2006 text: 2006-02-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Gynecologic oncology |
PublicationTitleAlternate | Gynecol Oncol |
PublicationYear | 2006 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Rothenberg, Kuhn, Burris, Nelson, Eckardt, Tristan-Morales (bib20) 1993; 11 Houghton, Cheshire, Hallman, Lutz, Friedman, Danks (bib23) 1995; 36 Rustin, Nelstrop, McClean, Brady, McGuire, Hoskins (bib25) 1996; 14 Markman, Hall, Spitz, Weiner, Carson, Van Le (bib5) 2002; 20 Fuchs, Moore, Harker, Villa, Rinaldi, Hecht (bib28) 2003; 21 Markman, Rothman, Hakes, Reichman, Hoskins, Rubin (bib3) 1991; 9 Takeuchi, Dobashi, Fujimoto, Tanaka, Suzuki, Terashima (bib9) 1991; 18 Parmar, Ledermann, Colombo, du Bois, Delaloye, Kristensen (bib4) 2003; 361 Nishio, Sugiyama, Shoji, Kitagawa, Ushijima, Kamura (bib31) 2005; 24 Bookman, Malmstrom, Bolis, Gordon, Lissoni, Krebs (bib7) 1998; 16 Markman, Zanotti, Webster, Peterson, Kulp, Belinson (bib6) 2003; 91 Abigerges, Chabot, Armand, Herait, Gouyette, Gandia (bib22) 1995; 13 Arbuck SG IS, Setser A, et al. The Revised Common Toxicity Criteria: Version 2.0. [cited; Available from Piccart, Green, Lacave, Reed, Vergote, Benedetti-Panici (bib15) 2000; 18 McGuire, Hoskins, Brady, Kucera, Partridge, Look (bib1) 1996; 334 Negoro, Fukuoka, Masuda, Takada, Kusunoki, Matsui (bib19) 1991; 83 Yonemori, Katsumata, Yamamoto, Kasamatsu, Yamada, Tsunematsu (bib29) 2005; 104 Markman, Hakes, Reichman, Lewis, Rubin, Jones (bib14) 1992; 10 Miller, Hoogstraten, Staquet, Winkler (bib24) 1981; 47 Yamanaka, Katsumata, Watanabe, Andoh, Mukai, Kitagawa (bib30) 2002; 21 Markman, Webster, Zanotti, Kulp, Peterson, Belinson (bib12) 2003; 90 Takeuchi, Takamizawa, Takeda, Ohkawa, Tamaya, Noda (bib17) 1991; 18 Ohe, Sasaki, Shinkai, Eguchi, Tamura, Kojima (bib18) 1992; 84 . Bodurka, Levenback, Wolf, Gano, Wharton, Kavanagh (bib8) 2003; 21 Gordon, Granai, Rose, Hainsworth, Lopez, Weissman (bib10) 2000; 18 Kawato, Aonuma, Hirota, Kuga, Sato (bib16) 1991; 51 Sorensen, Hoyer, Jakobsen, Malmstrom, Havsteen, Bertelsen (bib13) 2001; 81 Rowinsky, Grochow, Ettinger, Sartorius, Lubejko, Chen (bib21) 1994; 54 Rose, Blessing, Mayer, Homesley (bib11) 1998; 16 Sugiyama, Kamura, Kigawa, Terakawa, Kikuchi, Kita (bib27) 2000; 88 Piccart, Bertelsen, James, Cassidy, Mangioni, Simonsen (bib2) 2000; 92 Markman (10.1016/j.ygyno.2005.10.013_bib6) 2003; 91 Abigerges (10.1016/j.ygyno.2005.10.013_bib22) 1995; 13 Markman (10.1016/j.ygyno.2005.10.013_bib3) 1991; 9 Takeuchi (10.1016/j.ygyno.2005.10.013_bib9) 1991; 18 Markman (10.1016/j.ygyno.2005.10.013_bib12) 2003; 90 Bodurka (10.1016/j.ygyno.2005.10.013_bib8) 2003; 21 Markman (10.1016/j.ygyno.2005.10.013_bib14) 1992; 10 Houghton (10.1016/j.ygyno.2005.10.013_bib23) 1995; 36 Yamanaka (10.1016/j.ygyno.2005.10.013_bib30) 2002; 21 Miller (10.1016/j.ygyno.2005.10.013_bib24) 1981; 47 Parmar (10.1016/j.ygyno.2005.10.013_bib4) 2003; 361 Nishio (10.1016/j.ygyno.2005.10.013_bib31) 2005; 24 Negoro (10.1016/j.ygyno.2005.10.013_bib19) 1991; 83 Bookman (10.1016/j.ygyno.2005.10.013_bib7) 1998; 16 Kawato (10.1016/j.ygyno.2005.10.013_bib16) 1991; 51 Rose (10.1016/j.ygyno.2005.10.013_bib11) 1998; 16 Markman (10.1016/j.ygyno.2005.10.013_bib5) 2002; 20 Sugiyama (10.1016/j.ygyno.2005.10.013_bib27) 2000; 88 Piccart (10.1016/j.ygyno.2005.10.013_bib15) 2000; 18 McGuire (10.1016/j.ygyno.2005.10.013_bib1) 1996; 334 Rustin (10.1016/j.ygyno.2005.10.013_bib25) 1996; 14 Sorensen (10.1016/j.ygyno.2005.10.013_bib13) 2001; 81 Gordon (10.1016/j.ygyno.2005.10.013_bib10) 2000; 18 Takeuchi (10.1016/j.ygyno.2005.10.013_bib17) 1991; 18 Piccart (10.1016/j.ygyno.2005.10.013_bib2) 2000; 92 Rothenberg (10.1016/j.ygyno.2005.10.013_bib20) 1993; 11 10.1016/j.ygyno.2005.10.013_bib26 Ohe (10.1016/j.ygyno.2005.10.013_bib18) 1992; 84 Rowinsky (10.1016/j.ygyno.2005.10.013_bib21) 1994; 54 Yonemori (10.1016/j.ygyno.2005.10.013_bib29) 2005; 104 Fuchs (10.1016/j.ygyno.2005.10.013_bib28) 2003; 21 |
References_xml | – volume: 10 start-page: 243 year: 1992 end-page: 248 ident: bib14 article-title: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease publication-title: J. Clin. Oncol. contributor: fullname: Jones – volume: 20 start-page: 2365 year: 2002 end-page: 2369 ident: bib5 article-title: Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel–refractory ovarian cancer publication-title: J. Clin. Oncol. contributor: fullname: Van Le – volume: 92 start-page: 699 year: 2000 end-page: 708 ident: bib2 article-title: Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results publication-title: J. Natl. Cancer Inst. contributor: fullname: Simonsen – volume: 21 start-page: 291 year: 2003 end-page: 297 ident: bib8 article-title: Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer publication-title: J. Clin. Oncol. contributor: fullname: Kavanagh – volume: 334 start-page: 1 year: 1996 end-page: 6 ident: bib1 article-title: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer publication-title: N. Engl. J. Med. contributor: fullname: Look – volume: 24 year: 2005 ident: bib31 article-title: Phase II study of irinotecan plus oral etoposide in patients with platinum and taxane-resistant ovarian cancer publication-title: Proc.-Am. Soc. Clin. Oncol. contributor: fullname: Kamura – volume: 16 start-page: 405 year: 1998 end-page: 410 ident: bib11 article-title: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study publication-title: J. Clin. Oncol. contributor: fullname: Homesley – volume: 84 start-page: 972 year: 1992 end-page: 974 ident: bib18 article-title: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion publication-title: J. Natl. Cancer Inst. contributor: fullname: Kojima – volume: 91 start-page: 573 year: 2003 end-page: 576 ident: bib6 article-title: Phase 2 trial of single agent docetaxel in platinum and paclitaxel–refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum publication-title: Gynecol. Oncol. contributor: fullname: Belinson – volume: 11 start-page: 2194 year: 1993 end-page: 2204 ident: bib20 article-title: Phase I and pharmacokinetic trial of weekly CPT-11 publication-title: J. Clin. Oncol. contributor: fullname: Tristan-Morales – volume: 51 start-page: 4187 year: 1991 end-page: 4191 ident: bib16 article-title: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 publication-title: Cancer Res. contributor: fullname: Sato – volume: 36 start-page: 393 year: 1995 end-page: 403 ident: bib23 article-title: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors publication-title: Cancer Chemother. Pharmacol. contributor: fullname: Danks – volume: 104 start-page: 1204 year: 2005 end-page: 1212 ident: bib29 article-title: A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy publication-title: Cancer contributor: fullname: Tsunematsu – volume: 88 start-page: 2584 year: 2000 end-page: 2589 ident: bib27 article-title: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy publication-title: Cancer contributor: fullname: Kita – volume: 16 start-page: 3345 year: 1998 end-page: 3352 ident: bib7 article-title: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel publication-title: J. Clin. Oncol. contributor: fullname: Krebs – volume: 18 start-page: 579 year: 1991 end-page: 584 ident: bib17 article-title: An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers publication-title: Gan To Kagaku Ryoho contributor: fullname: Noda – volume: 90 start-page: 593 year: 2003 end-page: 596 ident: bib12 article-title: Phase 2 trial of single-agent gemcitabine in platinum–paclitaxel refractory ovarian cancer publication-title: Gynecol. Oncol. contributor: fullname: Belinson – volume: 21 year: 2002 ident: bib30 article-title: A dose finding study of irinotecan in combination with oral etoposide in patients with platinum treated advanced epithelial ovarian cancer publication-title: Proc.-Am. Soc. Clin. Oncol. contributor: fullname: Kitagawa – volume: 47 start-page: 207 year: 1981 end-page: 214 ident: bib24 article-title: Reporting results of cancer treatment publication-title: Cancer contributor: fullname: Winkler – volume: 18 start-page: 3093 year: 2000 end-page: 3100 ident: bib10 article-title: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer publication-title: J. Clin. Oncol. contributor: fullname: Weissman – volume: 81 start-page: 58 year: 2001 end-page: 62 ident: bib13 article-title: Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma publication-title: Gynecol. Oncol. contributor: fullname: Bertelsen – volume: 361 start-page: 2099 year: 2003 end-page: 2106 ident: bib4 article-title: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial publication-title: Lancet contributor: fullname: Kristensen – volume: 18 start-page: 1193 year: 2000 end-page: 1202 ident: bib15 article-title: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group publication-title: J. Clin. Oncol. contributor: fullname: Benedetti-Panici – volume: 13 start-page: 210 year: 1995 end-page: 221 ident: bib22 article-title: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients publication-title: J. Clin. Oncol. contributor: fullname: Gandia – volume: 54 start-page: 427 year: 1994 end-page: 436 ident: bib21 article-title: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks publication-title: Cancer Res. contributor: fullname: Chen – volume: 21 start-page: 807 year: 2003 end-page: 814 ident: bib28 article-title: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer publication-title: J. Clin. Oncol. contributor: fullname: Hecht – volume: 9 start-page: 389 year: 1991 end-page: 393 ident: bib3 article-title: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin publication-title: J. Clin. Oncol. contributor: fullname: Rubin – volume: 14 start-page: 1545 year: 1996 end-page: 1551 ident: bib25 article-title: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 publication-title: J. Clin. Oncol. contributor: fullname: Hoskins – volume: 18 start-page: 1681 year: 1991 end-page: 1689 ident: bib9 article-title: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers publication-title: Gan To Kagaku Ryoho contributor: fullname: Terashima – volume: 83 start-page: 1164 year: 1991 end-page: 1168 ident: bib19 article-title: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer publication-title: J. Natl. Cancer Inst. contributor: fullname: Matsui – volume: 91 start-page: 573 issue: 3 year: 2003 ident: 10.1016/j.ygyno.2005.10.013_bib6 article-title: Phase 2 trial of single agent docetaxel in platinum and paclitaxel–refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2003.08.001 contributor: fullname: Markman – volume: 81 start-page: 58 issue: 1 year: 2001 ident: 10.1016/j.ygyno.2005.10.013_bib13 article-title: Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma publication-title: Gynecol. Oncol. doi: 10.1006/gyno.2000.6089 contributor: fullname: Sorensen – volume: 16 start-page: 405 issue: 2 year: 1998 ident: 10.1016/j.ygyno.2005.10.013_bib11 article-title: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1998.16.2.405 contributor: fullname: Rose – volume: 18 start-page: 1193 issue: 6 year: 2000 ident: 10.1016/j.ygyno.2005.10.013_bib15 article-title: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2000.18.6.1193 contributor: fullname: Piccart – volume: 92 start-page: 699 issue: 9 year: 2000 ident: 10.1016/j.ygyno.2005.10.013_bib2 article-title: Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/92.9.699 contributor: fullname: Piccart – volume: 21 year: 2002 ident: 10.1016/j.ygyno.2005.10.013_bib30 article-title: A dose finding study of irinotecan in combination with oral etoposide in patients with platinum treated advanced epithelial ovarian cancer publication-title: Proc.-Am. Soc. Clin. Oncol. contributor: fullname: Yamanaka – volume: 9 start-page: 389 issue: 3 year: 1991 ident: 10.1016/j.ygyno.2005.10.013_bib3 article-title: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1991.9.3.389 contributor: fullname: Markman – volume: 16 start-page: 3345 issue: 10 year: 1998 ident: 10.1016/j.ygyno.2005.10.013_bib7 article-title: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1998.16.10.3345 contributor: fullname: Bookman – volume: 47 start-page: 207 issue: 1 year: 1981 ident: 10.1016/j.ygyno.2005.10.013_bib24 article-title: Reporting results of cancer treatment publication-title: Cancer doi: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 contributor: fullname: Miller – ident: 10.1016/j.ygyno.2005.10.013_bib26 – volume: 20 start-page: 2365 issue: 9 year: 2002 ident: 10.1016/j.ygyno.2005.10.013_bib5 article-title: Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel–refractory ovarian cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2002.09.130 contributor: fullname: Markman – volume: 104 start-page: 1204 issue: 6 year: 2005 ident: 10.1016/j.ygyno.2005.10.013_bib29 article-title: A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy publication-title: Cancer doi: 10.1002/cncr.21287 contributor: fullname: Yonemori – volume: 14 start-page: 1545 issue: 5 year: 1996 ident: 10.1016/j.ygyno.2005.10.013_bib25 article-title: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1996.14.5.1545 contributor: fullname: Rustin – volume: 13 start-page: 210 issue: 1 year: 1995 ident: 10.1016/j.ygyno.2005.10.013_bib22 article-title: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1995.13.1.210 contributor: fullname: Abigerges – volume: 51 start-page: 4187 issue: 16 year: 1991 ident: 10.1016/j.ygyno.2005.10.013_bib16 article-title: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 publication-title: Cancer Res. contributor: fullname: Kawato – volume: 88 start-page: 2584 issue: 11 year: 2000 ident: 10.1016/j.ygyno.2005.10.013_bib27 article-title: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy publication-title: Cancer doi: 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.3.CO;2-X contributor: fullname: Sugiyama – volume: 21 start-page: 291 issue: 2 year: 2003 ident: 10.1016/j.ygyno.2005.10.013_bib8 article-title: Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2003.02.091 contributor: fullname: Bodurka – volume: 11 start-page: 2194 issue: 11 year: 1993 ident: 10.1016/j.ygyno.2005.10.013_bib20 article-title: Phase I and pharmacokinetic trial of weekly CPT-11 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1993.11.11.2194 contributor: fullname: Rothenberg – volume: 18 start-page: 3093 issue: 17 year: 2000 ident: 10.1016/j.ygyno.2005.10.013_bib10 article-title: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2000.18.17.3093 contributor: fullname: Gordon – volume: 83 start-page: 1164 issue: 16 year: 1991 ident: 10.1016/j.ygyno.2005.10.013_bib19 article-title: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/83.16.1164 contributor: fullname: Negoro – volume: 361 start-page: 2099 issue: 9375 year: 2003 ident: 10.1016/j.ygyno.2005.10.013_bib4 article-title: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial publication-title: Lancet doi: 10.1016/S0140-6736(03)13718-X contributor: fullname: Parmar – volume: 10 start-page: 243 issue: 2 year: 1992 ident: 10.1016/j.ygyno.2005.10.013_bib14 article-title: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1992.10.2.243 contributor: fullname: Markman – volume: 90 start-page: 593 issue: 3 year: 2003 ident: 10.1016/j.ygyno.2005.10.013_bib12 article-title: Phase 2 trial of single-agent gemcitabine in platinum–paclitaxel refractory ovarian cancer publication-title: Gynecol. Oncol. doi: 10.1016/S0090-8258(03)00399-8 contributor: fullname: Markman – volume: 18 start-page: 579 issue: 4 year: 1991 ident: 10.1016/j.ygyno.2005.10.013_bib17 article-title: An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers publication-title: Gan To Kagaku Ryoho contributor: fullname: Takeuchi – volume: 36 start-page: 393 issue: 5 year: 1995 ident: 10.1016/j.ygyno.2005.10.013_bib23 article-title: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/BF00686188 contributor: fullname: Houghton – volume: 84 start-page: 972 issue: 12 year: 1992 ident: 10.1016/j.ygyno.2005.10.013_bib18 article-title: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/84.12.972 contributor: fullname: Ohe – volume: 18 start-page: 1681 issue: 10 year: 1991 ident: 10.1016/j.ygyno.2005.10.013_bib9 article-title: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers publication-title: Gan To Kagaku Ryoho contributor: fullname: Takeuchi – volume: 21 start-page: 807 issue: 5 year: 2003 ident: 10.1016/j.ygyno.2005.10.013_bib28 article-title: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2003.08.058 contributor: fullname: Fuchs – volume: 334 start-page: 1 issue: 1 year: 1996 ident: 10.1016/j.ygyno.2005.10.013_bib1 article-title: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199601043340101 contributor: fullname: McGuire – volume: 54 start-page: 427 issue: 2 year: 1994 ident: 10.1016/j.ygyno.2005.10.013_bib21 article-title: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks publication-title: Cancer Res. contributor: fullname: Rowinsky – volume: 24 year: 2005 ident: 10.1016/j.ygyno.2005.10.013_bib31 article-title: Phase II study of irinotecan plus oral etoposide in patients with platinum and taxane-resistant ovarian cancer publication-title: Proc.-Am. Soc. Clin. Oncol. contributor: fullname: Nishio |
SSID | ssj0003012 |
Score | 2.0700753 |
Snippet | Irinotecan is one of the drugs that might be effective against platinum- and taxanes-resistant epithelial ovarian cancer. We investigated efficacy and safety... |
SourceID | crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 412 |
SubjectTerms | Adult Aged Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Drug Administration Schedule Drug Resistance, Neoplasm Female Humans Irinotecan Middle Aged Organoplatinum Compounds - pharmacology Ovarian cancer Ovarian Neoplasms - drug therapy Platinum-resistant Retrospective Studies Second line treatment Taxanes-resistant Taxoids - pharmacology Weekly schedule |
Title | The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer |
URI | https://dx.doi.org/10.1016/j.ygyno.2005.10.013 https://www.ncbi.nlm.nih.gov/pubmed/16298422 |
Volume | 100 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7BIiEuFbSFUijyocembBw7cY4IgZauyqEqKrfIT7SIOqtteOylv52ZPGi5UKmnWJbsROPx-JvJzGeAj1KV1mXaJ1YbdFC4zxLlpcKW5YUpx1K7lu3zPJ9ciC-X8nIFjodaGEqr7G1_Z9Nba933HPbSPJzPZlTjS9d1SzWW1EqLVVjD40iIEawdnU0n508GGXW4Iw1vq6alGsiH2jSv5dUy1l1shbK80uwfB9Rfp8_pJrzqYSM76r5sC1Z8fA3rX_sf42_gAZeb_dLBN0umo2OemCG0XbI6MIR47L4lzmeuptAAdc4Ws0gMDToyhK1sTilx8fZn0o5u9INGE5igK07wMjbMz6l24waVldV36F7jMEv6sngLF6cn348nSX-pQmIROTVJWoyD0QgTrUudFq40mQnS4N7kWbCey1DmqRYicKHSTAlvQtAFblX0tLTLTLYNo1hH_w6YQu-K_ClfFlIEh7PlRvLChiAQ1YztLnwaJFnNO-6Makgqu65awdMtmJI6UfC7kA_Srp6pQIXW_eWBO93a_HlLzkslOH__v1PuwUYXa6G8lX0YNYtb_wHRR2MOYPXz7_Sg1zF6Tr_9mD4Cglrb7g |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZKV4K9IJYFtjx2feC4oY1jJ84RVVRlt-2plXqL_ERF4FTd7NJe-O3M5KHCBSRukSU70Xg8_sb55jMh74XMjU2Ui4zSkKAwl0TSCQlPhmU6Hwlla7XPRTpd8Zu1WPfIuKuFQVplG_ubmF5H67Zl2FpzuN1ssMYXr-sWciTwKc4ekRNEA8jr-vDzyPMAD24kw-uaaSE76aGa5HX4cghlc7KCHK84-cf29NveM3lGnragkX5svuuM9Fx4Th7P29_i52QPk03vlHfVgapgqUNdCGUOtPQUAB79UcvmU1viwQA2bnabgPoMKlAArXSLhLhw_z2qe1dqryAARpCII7gMFXVbrNz4Bq5KywdIrqGbQW_ZvSCryafleBq1VypEBnBTFcXZyGsFINHY2Cpuc51oLzSsTJZ445jweRorzj3jMk4kd9p7lcFChTxL2UQnL0k_lMFdECoht8JsyuWZ4N7CaKkWLDPec8A0IzMg150li22jnFF0lLKvRW14vANTYCMYfkDSztrFHw5QQGz_e8dXzdwc35KyXHLGXv_vkFfkyXQ5nxWzz4vbN-S0OXVBBstb0q929-4d4JBKX9Z-9guZR9sg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+safety+and+efficacy+of+the+weekly+dosing+of+irinotecan+for+platinum-+and+taxanes-resistant+epithelial+ovarian+cancer&rft.jtitle=Gynecologic+oncology&rft.au=Matsumoto%2C+Koji&rft.au=Katsumata%2C+Noriyuki&rft.au=Yamanaka%2C+Yasuhiro&rft.au=Yonemori%2C+Kan&rft.date=2006-02-01&rft.issn=0090-8258&rft.volume=100&rft.issue=2&rft.spage=412&rft.epage=416&rft_id=info:doi/10.1016%2Fj.ygyno.2005.10.013&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ygyno_2005_10_013 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon |